FXR (Farnesoid X Receptor, also known as NR1H4) is a nuclear receptor that functions as the primary sensor of bile acids in the body. FXR regulates bile acid synthesis, transport, and metabolism, while also playing important roles in glucose homeostasis, lipid metabolism, and inflammatory responses. In the central nervous system, FXR is expressed in neurons and glial cells, where it modulates neuroinflammation, cholesterol metabolism, and synaptic plasticity—making it a potential therapeutic target for neurodegenerative diseases.
FXR has the characteristic nuclear receptor domain architecture with several isoforms:
| Isoform |
Amino Acids |
Tissue Distribution |
| FXRα1 |
472 |
Liver, intestine, kidney |
| FXRα2 |
435 |
Liver, intestine |
| FXRβ |
458 |
Testis (in rodents) |
| FXRγ |
418 |
Brain, muscle |
¶ Domain Architecture
FXR Protein Structure
┌─────────────────────────────────────────────────────┐
│ AF-1 │ DBD │ Hinge │ LBD │ AF-2 │
│(1-50) │(51-110) │(111-180) │(181-400) │(401-472)│
└─────────────────────────────────────────────────────┘
DBD: Two C4-type zinc fingers
LBD: Ligand-binding domain with hydrophobic pocket
- AF-1 Domain: N-terminal activation function, isoform-specific
- DNA-binding Domain: Two zinc fingers for direct repeat-1 (DR-1) response elements
- Hinge Region: Flexible linker for conformational changes
- Ligand-binding Domain: Binds primary bile acids (CDCA > DCA > CA > UDCA)
- AF-2 Helix: Completes the transcriptionally active conformation
FXR is the master regulator of bile acid homeostasis:
-
Bile Acid Synthesis Feedback:
- Activates CYP7A1 repression via FGF19 signaling
- Inhibits bile acid synthesis when levels are high
- Coordinates hepatic and intestinal signaling
-
Bile Acid Transport:
- Regulates BSEP (bile salt export pump)
- Controls NTCP (sodium taurocholate cotransporter)
- Modulates OSTα/β (organic solute transporter)
-
Enterohepatic Circulation:
- FGF19/15 signaling from intestine to liver
- Coordinated regulation of bile acid pool
Glucose Homeostasis:
- Enhances insulin sensitivity
- Suppresses gluconeogenesis
- Improves β-cell function
Lipid Metabolism:
- Inhibits de novo lipogenesis
- Reduces triglycerides
- Modulates VLDL secretion
Anti-inflammatory Effects:
- Inhibits NF-κB transcription
- Reduces inflammatory cytokines
- Protects against metabolic inflammation
FXR has emerged as a significant player in AD pathogenesis:
Cholesterol Metabolism:
Neuroprotection:
- FXR agonists reduce amyloid-β toxicity in models
- Improves synaptic plasticity and memory
- Reduces oxidative stress
Neuroinflammation:
- Suppresses microglial activation
- Reduces inflammatory cytokine expression
- Protects against neuroinflammation
Therapeutic Potential:
- FXR agonists in clinical development for AD
- Combination approaches with other targets
- Gene expression modulators
FXR provides neuroprotection in PD models:
Dopaminergic Neurons:
- Protects against 6-OHDA toxicity
- Reduces mitochondrial dysfunction
- Enhances neuronal survival
Neuroinflammation:
- Modulates glial cell activation
- Suppresses inflammatory responses
- Reduces dopaminergic neuron loss
Potential Therapeutics:
- FXR agonists show promise in preclinical studies
- Obeticholic acid (OCA) being investigated
- Cholesterol-lowering effects beneficial
- Lipid metabolism modulation
- Anti-inflammatory effects
- Motor neuron protection
- Myelin lipid regulation
- Anti-inflammatory properties
- Demyelination protection
| Gene Variant |
Effect |
Disease Association |
| NR1H4 variants |
Altered bile acid sensing |
AD risk |
| FXR expression |
Modified function |
PD progression |
| FGF19 signaling |
Metabolic changes |
Neurodegeneration |
| Partner |
Interaction |
Function |
| RXR |
Heterodimer |
DNA binding |
| SHP |
Coregulator |
Transcriptional repression |
| PGC-1α |
Coactivator |
Metabolic gene activation |
| NCoR/SMRT |
Corepressor |
Silencing |
- Bile Acid Metabolism: CYP7A1, BSEP, NTCP, OSTα/β
- Lipid Metabolism: ApoC-II, ApoC-III, PLTP
- Glucose Metabolism: PEPCK, G6Pase
- Transport: OSTα, OSTβ, MRP3
- Neurons: High expression in cortex, hippocampus, cerebellum
- Astrocytes: Moderate expression
- Microglia: Lower expression, increases with activation
- Oligodendrocytes: Present but lower levels
- Highest in cerebral cortex and hippocampus
- Moderate in basal ganglia
- Lower in brainstem
- Bile Acid Levels: Ligand-dependent activation
- Inflammatory Signals: Suppressed by NF-κB
- Metabolic State: Regulated by nutritional status
-
Obeticholic Acid (OCA): Semi-synthetic bile acid
- FDA-approved for PBC
- Being studied for NASH and AD
- Good safety profile
-
GW4064: Synthetic FXR agonist
- Research compound
- High potency
- Poor brain penetration
-
Cilofexor (GS-9674): Non-bile acid FXR agonist
- Improved safety profile
- Being studied for metabolic diseases
- Peripheral Effects: Liver and gastrointestinal actions
- Brain Penetration: Limited for CNS applications
- Pruritus: Side effect of potent agonists
- FGF19 Analogs: Target CNS expression
- Gene Therapy: Tissue-specific modulation
- Small Molecule Modulators: Selective CNS effects